CD19/BCMA CAR-T cell therapy for tough autoimmune diseases in kids
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy (CAR-T cells designed to target CD19 and BCMA) for children and teenagers with severe autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this one-time infusion can help control the disease and reduce the need for long-term steroids and other drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 19 years old.
- You have one of these autoimmune diseases: lupus with kidney inflammation, scleroderma, inflammatory muscle disease, IgA nephropathy, or steroid-resistant nephrotic syndrome.
- You have tried standard treatments (like high-dose steroids and at least two other immune-suppressing drugs) for several months and they have not worked or you cannot tolerate them.
- Your organs (like bone marrow, liver, kidneys, heart, and lungs) are functioning well enough to safely receive this therapy.
- You have not had CAR-T therapy before, and you do not have an uncontrolled serious infection or advanced heart/lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
This trial tests a new type of cell therapy (SCAR02) that targets two proteins on immune cells to help calm down overactive autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis. It may be an option if standard treatments haven't worked well enough.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like lupus, scleroderma, vasculitis, muscle inflammation, and Sjögren's syndrome that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and reduce the B cells driving your disease.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.